Get the Stockscreener App
18.68
2.86%
0.52
After Hours:
18.68
Bicara Therapeutics Inc stock is traded at $18.68, with a volume of 364.88K.
It is up +2.86% in the last 24 hours and up +6.68% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$18.16
Open:
$18.55
24h Volume:
364.88K
Relative Volume:
0.69
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
$-121.52M
P/E Ratio:
-8.3782
EPS:
-2.2296
Net Cash Flow:
$-113.06M
1W Performance:
+1.47%
1M Performance:
+6.68%
6M Performance:
+74.58%
1Y Performance:
+43.36%
1-Day Range:
$18.36
$19.50
1-Week Range:
$17.68
$19.50
52-Week Range:
$7.80
$20.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.68 | 1.18B | 0 | -121.52M | -113.06M | -2.2296 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
BCAX (NASDAQ: BCAX) issuer to sell 5,500 shares; insider sales disclosed - Stock Titan
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera - Proactive financial news
Bicara Therapeutics stock gains on BofA initiation - Investing.com
Bicara Therapeutics stock gains on BofA initiation By Investing.com - Investing.com South Africa
BCAX: B of A Securities Initiates Coverage with 'Buy' Rating | B - GuruFocus
BofA Initiates Bicara Therapeutics at Buy With $35 Price Target - marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 9,200 Shares - MarketBeat
Ivan Hyep, Bicara Therapeutics CFO, sells $170k in BCAX stock - Investing.com
Bicara Therapeutics (BCAX) CFO exercises options and sells 9,200 shares under 10b5-1 plan - Stock Titan
BCAX (NASDAQ: BCAX) insider sells 9,200 shares via option exercise - Stock Titan
Bicara Therapeutics Inc. schedules March 30 Q4 and 2025 earnings call for investors - Traders Union
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET - Bitget
Bicara Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
BCAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $30,244.20 in Stock - MarketBeat
Claire Mazumdar Sells 6,499 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 6,905 Shares - MarketBeat
Bicara therapeutics CEO Mazumdar sells $282k in BCAX stock By Investing.com - Investing.com Canada
Bicara therapeutics CEO Mazumdar sells $282k in BCAX stock - Investing.com
Bicara Therapeutics Insider Sold Shares Worth $282,366, According to a Recent SEC Filing - marketscreener.com
Bicara Therapeutics (BCAX) CEO sells 15,000 shares after option exercise - Stock Titan
BCAX (NASDAQ: BCAX) affiliate sells shares; planned 1,596‑share option exercise - Stock Titan
Bicara Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
Bicara Therapeutics Inc. exposes urgent need for improved therapies in HPV negative recurrent HNSCC - Traders Union
Cantor Fitzgerald L. P. Takes $1.58 Million Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Affiliate plans to sell 6,499 BCAX shares (NASDAQ: BCAX) - Stock Titan
Aug Sentiment: How much upside does Bicara Therapeutics Inc have2026 Key Highlights & High Win Rate Trade Alerts - baoquankhu1.vn
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock - MarketBeat
Bicara Therapeutics (BCAX) president sells $245,713 in stock - Investing.com
Bicara Therapeutics (BCAX) president sells $245,713 in stock By Investing.com - Investing.com Canada
Bicara Therapeutics (BCAX) COO exercises options and sells shares - Stock Titan
Bicara Therapeutics Inc. targets tumor microenvironment with combined EGFR and TGF beta inhibition - Traders Union
BCAX (BCAX) Form 144 shows option exercises and Ryan Cohlhepp sales - Stock Titan
Cantor Fitzgerald L. P. Invests $1.58 Million in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference - MarketBeat
Bicara Therapeutics stock hits 52-week high at 19.72 USD By Investing.com - Investing.com Nigeria
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics CEO Sells Shares - TradingView
Bicara Therapeutics (NASDAQ: BCAX) CEO exercises options, sells 36,766 shares - Stock Titan
Bicara Therapeutics (BCAX) Is Up 11.9% After US$172.5 Million Equity Raise And CEO Share Sale - simplywall.st
United StatesGoodwin Advises Bicara Therapeutics On Closing Of $172.5 Million Oversubscribed Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Bicara Therapeutics Inc. targets fibrotic tumor barriers in HPV negative R M HNSCC - Traders Union
Bicara Therapeutics stock hits 52-week high at 19.72 USD - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After FICERA Data And Capital Raise - simplywall.st
Stock Report: Can Bicara Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - Naître et grandir
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeuti - GuruFocus
Bicara Therapeutics Inc Stock (BCAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):